CLAIMS

1. A peptide constituting a T-cell epitope obtainable from the minor Histocompatibility antigen HA-1 comprising the sequence VLXDDLLEA or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue.

2. An immunogenic polypeptide obtainable from the minor Histocompatibility antigen HA-1 comprising the sequence VLXDDLLEA or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue.

3. A peptide or polypeptide according to claim 1 or 2, comprising the sequence VLHDDLLEA.

4. Vaccine comprising an epitope or a polypeptide according to any one of claims 1-3.

5. A pharmaceutical formulation comprising an epitope or a polypeptide according to any one of claims 1-3.

6. Peptide or polypeptide according to claims 1-3 for use as a medicine.

7. Use of a peptide or polypeptide according to claims 1-3 in the preparation of a medicament for the induction of tolerance for transplants to prevent rejection and/or Graft versus Host disease or to treat (auto)immune disease.

8. A method for the elimination of a group of (neoplastic) hematopoietic cells presenting a peptide in the context of HLA class 1 according to any of one of claims 1-3, whereby elimination is induced directly of indirectly by specific recognition of said peptide in said context.

9. Analog of the peptide according to claim 1, which is an antagonist for the activity of T cells recognizing said peptide.

10. Method for the generation of antibodies, T cell receptors, anti-idiotypic B-cells or T-cells, comprising the step of immunization of a mammal with a peptide or a polypeptide according to claim 1 or 2.

11. Antibodies, T-cell receptors, B-cells or T-cells obtainable by the method of claim 10.

12. A method for the generation of a cytotoxic T-cell against a minor antigen, comprising contacting a hematopoietic cell, preferably a dendritic cell with a peptide, preferably in the context of HLA class I, or a polypeptide according to anyone of claims 1-3.

13. A method according to claim 12, wherein said hematopoietic cell is negative for said minor antigen.

14. A method according to claim 12 or 13, wherein said minor antigen is HA-1.

15. A method according to any one of claims 12-14 wherein said contacting is carried out ex vivo.

16. A method according to any one of claims 12-15, wherein said cytotoxic T-cell is provided with a suicide gene.

17. A method according to anyone of claims 12-16, whereby said cytotoxic T-cell is immortalized.

18. A cyotoxic T-cell or a derivative or an active fragment thereof, obtainable by a method according to any one of claims 12-17.

19. A cytotoxic T-cell according to claim 18, which is capable of expansion.